author-photo

Susan E. Moody

Novartis
University of Pennsylvania

37

Papers

2929

Citations

Citation Trend

Filter By

Papers (37) Sort By

Journal Conference Others

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

2021 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (7)
Cellular dormancy in minimal residual disease following targeted therapy.

2021 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (17)
Abstract CT034: Phase I study of WNT974 + spartalizumab in patients (pts) with advanced solid tumors

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors

2020 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Efficacy of Nazartinib (EGF816) in Adults With EGFR-mutant Non-Small-Cell Lung Carcinoma: A Multicentre, Open-Label, Phase 1 Study

2020 The Lancet Respiratory Medicine
Show All
- Source
- Cite
- Save
Citations (19)
Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition

2020
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers.

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (18)
SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (36)